Skip to main content
Clinical Trials/EUCTR2007-007132-25-DE
EUCTR2007-007132-25-DE
Active, not recruiting
Not Applicable

A randomized, double blind, parallel, placebo controlled, exploratory study to assess the effect of EA-230 on renal function and on safety and tolerability in patients at increased risk of developing renal failure following major cardiac on-pump surgery.

EBI Anti Sepsis B.V.0 sites150 target enrollmentFebruary 11, 2009

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
EBI Anti Sepsis B.V.
Enrollment
150
Status
Active, not recruiting
Last Updated
14 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 11, 2009
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
EBI Anti Sepsis B.V.

Eligibility Criteria

Inclusion Criteria

  • 1\.Male or female patients of at least 18 years old
  • 2\.Patients who are scheduled to undergo major elective cardiac surgery
  • 3\.Patients who are willing to provide informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • 1\.Patients undergoing emergency surgery.
  • 2\.Severe congestive heart failure EF \< 20 %.
  • 3\.Congenital heart disease other than corrected atrial septum defect or corrected ventricular septum defect.
  • 4\.Patients with a known malignancy or a history of malignancy, other than successfully treated non\-metastatic basal or squamous cell carcinoma of the skin
  • 5\.Previous organ transplantation.
  • 6\.Active or uncontrolled liver disease/hepatitis.
  • 7\.Any disease that (a) has required immunosuppressive drugs (including oral or parenteral corticosteroids) during the past 6 months, or that (b) is fairly likely to require administration of such drugs in the post\-operative period. Examples of such diseases include COPD, asthma, chronic bronchitis, auto\-immune diseases, and so on. However, inhaled or topical steroids are permitted.
  • 8\.Patients who are unable themselves to sign the informed consent form, whether because of strokes or cognitive defects (dementia or otherwise).
  • 9\.Confirmed HIV\-positivity.
  • 10\.Active (acute) infectious disease and/or severe chronic infectious disease requiring antibiotic treatment.

Outcomes

Primary Outcomes

Not specified

Similar Trials